China SXT Pharmaceuticals, Inc.
corporate_fare Company Profile
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for SXTC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-22, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for SXTC spans 6-K, 424B5, F-3, 20-F.
Recent high-impact activity:
- China SXT Sets 1-for-100 Share Consolidation Effective October 26
- China SXT Closes $12M Offering With Zero-Price Warrants and $12M Over-Allotment Option
- China SXT Finalizes $12M Offering With Zero-Price Warrants That Could Add 72M Shares
- China SXT Launches $12M Registered Direct Offering, Diluting Existing Holders
- China SXT Resets Financing Floor Price to $0.20 After 1-for-80 Reverse Split
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 721,044 shares in SXTC as of the October 15, 2026 settlement, a 999.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 30, 2026, 46.5% of SXTC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for SXTC, detected from its recent SEC filings · based on capital-structure filings through 2026-10-21.
$12M Offering Finalized at $1.50/Unit · Zero-Price Exercise Warrants
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
SXTC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.